AbbVie

See the following -

Doctors Promoting Treatments on Social Media Routinely Fail to Disclose Ties to Drug Makers

Sheila Kaplan | STAT | February 29, 2016

Physicians across the United States routinely offer medical advice on social media — but often fail to mention that they have accepted tens and sometimes hundreds of thousands of dollars from the companies that make the prescription drugs they tout. A STAT examination of hundreds of social media accounts shows that health care professionals virtually never note their conflicts of interest, some of them significant, when promoting drugs or medical devices on sites such as Facebook, Instagram, and Twitter. The practice cuts across all specialties...

Read More »

How Big Business Buys The Right To Dodge US Taxes

Jason DeCrow | Quartz | August 26, 2014

...[F]irms like Apple, Google, or General Electric find ways avoid taxes on billions of dollars of global income. It may be bad for US taxpayers but, hey, blame lawmakers for doing such a crappy job; the companies are just following the rules that have been created for them...

Read More »

How Google Plans to Reinvent Healthcare

Cheryl Swanson | The Motley Fool | September 3, 2016

Glucose-monitoring contact lenses for diabetics, wrist computers that read diagnostic nanoparticles injected in the blood stream, implantable devices that modify electrical signals that pass along nerves, medication robots, human augmentation, human brain simulation -- the list goes on. That's not an inventory of improbable CGI effects from the latest sci-fi movie, it's a list of initiatives being tackled by Alphabet's Google Life Sciences research unit, recently rebranded Verily...

Read More »

Secret Document Trove Reveals Bold ‘Crusade’ to Make OxyContin a Blockbuster

David Armstrong | STAT | September 22, 2016

The doughnut ploy, highlighted in a trove of internal documents obtained by STAT, shows the lengths to which Abbott went to hook in doctors and make OxyContin a billion-dollar blockbuster. The sales force bought takeout dinners for doctors and met them at bookstores to pay for their purchases. In memos, the sales team referred to the marketing of the drug as a “crusade,” and their boss called himself the “King of Pain.”

Read More »

TPP Treaty Could be a Serious Threat to US Public Health System

While trade agreements may seem to be another, albeit international species of wonkery, these agreements could have major effects on patients' and the public's health.  Since these concerns have been essentially ignored by the US medical and health care literature, (although they have appeared in UK journals, Australian, and New Zealand journals in English), they I will discuss them below. Worthy of further discussion is the possibility that these potential threats to health care and public health may arise not just from ideological disagreements, but also from health care corporations' increasing capture of government, facilitated by the conflicts of interest generated by the revolving door. Read More »

Why Opening Up Clinical Trials Data Is Good For Pharma Companies

Glyn Moody | TechDirt | November 5, 2013

Earlier this year we wrote about how AbbVie, the pharma company spun out of Abbott Laboratories, had gone to court to stop the European Medicines Agency (EMA) from releasing clinical trials information about one of its drugs. Read More »